SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

13 Aug 2022 Evaluate
A minor change in the total revenue was seen in the June 2022 quarter. The total revenue for the quarter stood at Rs. 4030.23 millions against Rs. 3844.53 millions during year ago period.Handsome Net Profit growth of 90.24% reported above the corresponding previous quarter figure of Rs. 39.36 millions to Rs. 20.69 millions.Operating profit surged to 422.09 millions from the corresponding previous quarter of 407.87 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 4030.23 3844.53 4.83 4030.23 3844.53 4.83 16682.56 15428.96 8.12
Other Income 3.64 51.46 -92.93 3.64 51.46 -92.93 112.93 27.22 314.88
PBIDT 422.09 407.87 3.49 422.09 407.87 3.49 1701.31 1129.49 50.63
Interest 213.66 257.45 -17.01 213.66 257.45 -17.01 788.10 1120.32 -29.65
PBDT 208.43 150.42 38.57 208.43 150.42 38.57 913.21 -243.98 -474.30
Depreciation 146.95 142.78 2.92 146.95 142.78 2.92 569.68 602.53 -5.45
PBT 61.48 7.64 704.71 61.48 7.64 704.71 343.53 -846.51 -140.58
TAX 22.12 -13.05 -269.50 22.12 -13.05 -269.50 90.34 -115.04 -178.53
Deferred Tax 22.12 -13.05 -269.50 22.12 -13.05 -269.50 90.34 -200.90 -144.97
PAT 39.36 20.69 90.24 39.36 20.69 90.24 253.19 -731.47 -134.61
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 9.06 9.18 -1.28 10.47 10.61 -1.28 8.84 6.41 37.98

Nectar Lifesciences Share Price

12.26 0.32 (2.68%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×